Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib in Children and Adolescents With Juvenile Idiopathic Arthritis
NCT06222034Phase 1Terminated
- Sponsor
- Alfasigma
- Start
- May 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of filgotinib in juvenile idiopathic arthritis (JIA) (3 arms), sponsored by Alfasigma. Primary endpoints: Maximum observed plasma concentration at steady state of filgotinib at Day 10, Maximum observed plasma concentration at steady state of GS-829845 at Day 10 and 4 more. Started May 2024; status: terminated.
02
Drugs
filgotinib
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NCT06222034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06222034.